In Response
- PMID: 41201440
- DOI: 10.1213/ANE.0000000000007793
In Response
Conflict of interest statement
Conflicts of Interest: K. A. Tanaka has received research support from Octapharma and Grifols; K. E. Stewart has served on advisory boards or as a consultant for Bayer, CSL Behring, Medexus, Novo Nordisk, Pfizer, and Sanofi.
References
-
- Pivalizza E. Major arthroplasty in patients with hereditary bleeding disorders. Anesth Analg. In Press. 2025.
-
- Stewart KE, Pak A, Kwak J, et al. Bleeding complications, transfusion, and acute care costs after major arthroplasty in patients with hereditary bleeding disorders: a National Healthcare Database Analysis. Anesth Analg. 2025;140:1479–1487.
-
- FY23 Inpatient Prospective Payment System Proposed Rule. Cited July 3, 2025. Accessed July 3, 2025. Available at: https://www.hematology.org/advocacy/testimony-and-correspondence/ash-fy2...
-
- Rhoades R, French Z, Yang A, Walsh K, Drelich DA, McKenzie SE. Perioperative outcomes of patients with bleeding disorders undergoing major surgery at an academic hemophilia treatment center. Clin Appl Thromb Hemost. 2023;29:10760296231165056.
-
- Yaoi H, Shida Y, Ogiwara K, Hosokawa K, Shima M, Nogami K. Role of red blood cells in the anemia-associated bleeding under high shear conditions. Haemophilia. 2017;23:750–758.
LinkOut - more resources
Full Text Sources
